Bayer Aktiengesellschaft (ETR: BAYN)
Germany
· Delayed Price · Currency is EUR | Market Cap | 19.44B |
| Revenue (ttm) | 46.74B |
| Net Income (ttm) | -880.00M |
| Shares Out | 982.42M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | 4.25 |
| Dividend | 0.11 (0.56%) |
| Ex-Dividend Date | n/a |
| Volume | 3,072,022 |
| Open | 19.68 |
| Previous Close | 19.72 |
| Day's Range | 19.47 - 19.99 |
| 52-Week Range | 18.41 - 35.77 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 5, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare produc... [Read more]
Financial Performance
Financial StatementsNews
Orion's collaboration partner Bayer submits application in China for third indication of darolutamide
ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET Orion's collaboration partner Bayer submits application in China for third indication of darolutamide Orion's collaboration partner ...
Bayer wins last pending Roundup case in Australia
Bayer Secures End of Roundup Weedkiller Litigation in Australia
The German pharmaceutical and agricultural conglomerate said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer.
Bayer Secures End of Roundup Weedkiller Litigation in Australia
The German pharmaceutical and agricultural conglomerate said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer.
Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia
LEVERKUSEN, Germany--(BUSINESS WIRE)--The Federal Court of Australia brought an end to the last Roundup™ case in Australia, closing all pending injury litigation there. The Court granted the plaintiff...
Bayer: Sell And Be Done With It
A year after Bayer got rid of bosses and asked staff to self-organize, its CEO says attrition has fallen
Bayer told workers to self-organize last year as part of a plan to save €2 billion in costs by 2026.
Bayer's CEO said budgets represent the worst of corporate bureaucracy. He decided to turn the process on its head.
Bayer CEO Bill Anderson says "everyone hates" the budget process and the bureaucracy involved. So he implemented 90-day budget cycles.
Bayer Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.
Bayer Eye Drug Shows Positive Results in Late-Stage Trial
Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for people suffering from some retinal diseases.
Bayer Partners with America's Grow-A-Row to Aid in the Fight Against Hunger in New Jersey
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced the successful completion of its fall employee engagement campaign with America's Grow-a-Row (AGAR), a New Jersey-based, nonprofit farm where approxima...
Bayer Gets EU Backing for Heart Drug, Easing Patent Concerns
Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the looming impact of expiring patents.
Class action members left shocked by decision that ruled in favour of pharmaceutical giant Bayer
The Essure was designed by Bayer as a permanent contraceptive device.
Australian women lose class action against Bayer over birth control device Essure
A Victorian judge has ruled that a group of Australian women's allegations over the Essure birth control device were "far from compelling".
Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again
Bayer Showcases Growing Radiology Portfolio at RSNA 2024
CHICAGO--(BUSINESS WIRE)--Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline as well as innovations around Artificial Intelligence (AI) and will...
Watermelon Seeds Market Analysis Report 2025-2030, Featuring Bayer CropScience, Vilmorin & Cie, Syngenta, Origene Seeds, GoldSupplier, Tokita Seed Co., Emerald Seed Company & Hazera
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Watermelon Seeds Market Size, Share & Trends Analysis Report by Type (Raw, Roasted, Dried), Distribution Channel, Region and Segment Forecasts, 2025-2030...
Dhanuka Agritech expands global reach with acquisition of Bayer AG’s active ingredients
This acquisition will allow Dhanuka to manufacture and sell Iprovalicarb and Triadimenol, including their associated brand Melody, across global markets.
Bayer's (BAYRY) Nubeqa sNDA for Prostate Cancer Accepted by FDA
Bayer's (BAYRY) Nubeqa sNDA for Prostate Cancer Accepted by FDA
Bayer Announces ‘Project Enhanced S3' to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects
ST. LOUIS--(BUSINESS WIRE)--Bayer announced today an expanded approach to its programs that sequester carbon and reduce emissions for companies along the food value chain through regenerative agricult...
Cytokinetics and Bayer partner to develop for aficamten in Japan
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HCM Therapy
Bayer (BAYRY) and Cytokinetics (CYTK) Collaborate on Japanese HCM Therapy
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular bu...
Bayer Faces Investor Pressure to Accelerate Turnaround Amid Record Lows
Bayer is under growing pressure from investors to expedite its turnaround strategy as CEO Bill Anderson grapples with slumping earnings and a 20-year low in the company’s share price following a stark...